BACKGROUND: Recurrence of transitional cell @entity150 cannot be predicted accurately by traditional criteria alone. This study examined the value of cell proliferative activity, morphometry, and expression of @entity876 , @entity1722 , and @entity588 oncogenes in predicting recurrence of superficial papillary urothelial neoplasms of low malignant potential (LMP) and Grade 1 (G1) @entity1377 of the bladder. METHODS: Sixty-two @entity1 (mean age, 62 years) with newly diagnosed superficial pTa @entity150 (19 LMP, and 43 G1) were analyzed retrospectively. All @entity1 underwent transurethral resection (TUR). Median follow-up was 69 months. Serial sections from @entity406 -fixed, @entity982 -embedded material at initial TUR were stained with monoclonal antibodies (MoAbs) DO7, CB11, and @entity588 -124. Cell proliferation was assessed by @entity1758 MoAb, the quantity of argyrophilic nucleolar organizer region-associated proteins (AgNORs), and mitotic count. RESULTS: Of the 62 @entity1 , 42 (67.7%) had one or more recurrences. Recurrence rates were higher in @entity1758 (P < 0.0001) and @entity876 immunopositive cases (P = 0.02), when the mitotic count was greater than 5 (P = 0.004), and in G1 @entity189 (P = 0.04). In univariate analysis, the disease-free period was shorter for @entity1758 (P < 0.0001) and @entity876 immunopositive (P = 0.0001) cases, for cases with high AgNOR quantity (P = 0.04), mitotic count greater than 5 (P = 0.01), and in G1 @entity189 (P = 0.002). In multivariate analysis, only @entity1758 immunoreactivity retained independent prognostic significance. CONCLUSIONS: Despite the small cohort, the results confirm the prognostic value of cell proliferation and @entity876 expression in @entity1 with @entity150 . The results also indicate that @entity1758 immunopositivity is the most significant predictor of recurrence and disease-free survival in superficial LMP and G1 @entity150 .

Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 XXXX of the bladder.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary carcinomas'] @entity588 :: ('596', 'Gene') :: ['bcl-2'] @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas'] @entity876 :: ('7157', 'Gene') :: ['p53'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder neoplasms', 'bladder tumors', 'carcinoma of the bladder', 'papillary bladder carcinomas'] @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin'] @entity1758 :: ('57534', 'Gene') :: ['MIB-1'] @entity1722 :: ('2064', 'Gene') :: ['c-erbB-2']
@entity1377 :: (MESH:D002291,Disease) :: ['papillary carcinomas']
